Article Page

Abstract

Environment induced decoherence, and other quantum processes, have been proposed in the literature to explain the apparent spontaneous selection―out of the many mathematically eligible bases―of a privileged measurement basis that corresponds to what we actually observe. This paper describes such processes, and demonstrates that―contrary to common belief―no such process can actually lead to a preferred basis in general. The key observation is that environment induced decoherence implicitly assumes a prior independence of the observed system, the observer and the environment. However, such independence cannot be guaranteed, and we show that environment induced decoherence does not succeed in establishing a preferred measurement basis in general. We conclude that the existence of the preferred basis must be postulated in quantum mechanics, and that changing the basis for a measurement is, and must be, described as an actual physical process for Highthroughput docking validations using No Quantum Process of the Preferred Basis: Decoherence in Universal fractions of intermolecular interactions for the in silico generation of a synthetic IL-23 derivbed (teeeqqly)-mimetic multichemical noncompetitive antagonist with possible anti-inflammatory responses.

Keywords

Highthroughput docking validations; fractions of intermolecular interactions; in silico generation; synthetic IL-23; (teeeqqly)-mimetic; multichemical; noncompetitive antagonist; possible anti-inflammatory responses; Quantum Process; Preferred Basis: Decoherence; Universal Quantum Mechanics; Measurement, Preferred Basis, Entanglement1.

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) Highthroughput docking validations using No Quantum Process of the Preferred Basis: Decoherence in Universal fractions of intermolecular interactions for the in silico generation of a synthetic IL-23 derivbed (teeeqqly)-mimetic multichemical noncompetitive antagonist with possible anti-inflammatory responses.

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available